Holen Sie sich die Stockscreener-App
422.00
1.21%
5.04
Vorhandelsmarkt:
422.00
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt VRTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$416.96
Offen:
$422.73
24-Stunden-Volumen:
1.63M
Relative Volume:
1.14
Marktkapitalisierung:
$108.68B
Einnahmen:
$10.63B
Nettoeinkommen (Verlust:
$-479.80M
KGV:
-212.06
EPS:
-1.99
Netto-Cashflow:
$-1.35B
1W Leistung:
+3.04%
1M Leistung:
-10.07%
6M Leistung:
-13.59%
1J Leistung:
-2.71%
1-Tages-Spanne:
$419.27
$428.25
1-Wochen-Bereich:
$397.25
$428.25
52-Wochen-Spanne:
$377.85
$519.88
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Firmenname
Vertex Pharmaceuticals Inc
Sektor
Branche
Telefon
(617) 341-6393
Adresse
50 NORTHERN AVENUE, BOSTON, MA
Vergleichen Sie VRTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-20 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-19 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Hochstufung | Jefferies | Hold → Buy |
| 2024-11-14 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-08-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-04-11 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-02-06 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Herabstufung | Maxim Group | Buy → Hold |
| 2024-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Herabstufung | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Eingeleitet | William Blair | Outperform |
| 2023-05-04 | Fortgesetzt | Piper Sandler | Overweight |
| 2023-03-21 | Eingeleitet | Bernstein | Outperform |
| 2023-01-18 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-01-17 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Hochstufung | Maxim Group | Hold → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-05-06 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Bestätigt | JP Morgan | Overweight |
| 2022-01-27 | Bestätigt | Morgan Stanley | Underweight |
| 2022-01-27 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-01-27 | Bestätigt | Stifel | Hold |
| 2022-01-27 | Bestätigt | Wolfe Research | Outperform |
| 2022-01-20 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-19 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Herabstufung | Stifel | Buy → Hold |
| 2021-09-07 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Fortgesetzt | Wolfe Research | Outperform |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-30 | Eingeleitet | Daiwa Securities | Outperform |
| 2020-11-30 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Eingeleitet | Bernstein | Outperform |
| 2020-10-28 | Eingeleitet | UBS | Buy |
| 2020-07-31 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-28 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-09-03 | Hochstufung | Goldman | Neutral → Buy |
| 2019-08-01 | Herabstufung | Needham | Buy → Hold |
| 2019-05-23 | Fortgesetzt | Citigroup | Buy |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-12 | Eingeleitet | Evercore ISI | In-line |
| 2019-03-26 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
Vertex Pharmaceuticals Inc Aktie (VRTX) Neueste Nachrichten
MassMutual Private Wealth & Trust FSB Has $2.51 Million Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Merit Financial Group LLC Raises Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Zhang Financial LLC Boosts Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Diversify Wealth Management LLC Raises Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
InTrack Investment Management Inc Has $878,000 Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
J2 Capital Management Inc Invests $270,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
McKesson, Vertex Pharmaceuticals among top healthcare Quant picks before Q4 earnings - MSN
Avanza Fonder AB Takes $11.34 Million Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by First Pacific Financial - MarketBeat
RDA Financial Network Trims Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
3 Unstoppable Stocks to Buy in 2025 - The Motley Fool
Vertex's Pain Drug: Big Pharma's Next Major Success? - MSN
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Empirical Asset Management LLC Increases Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Channel Wealth LLC Invests $716,000 in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Gateway Investment Advisers LLC - MarketBeat
Vertex Pharmaceuticals (VRTX) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
HHS says Vertex is ‘grasping at straws’ with Casgevy fertility suit - PharmaLive
Should You Buy Vertex Pharmaceuticals Stock Hand Over Fist Before Jan. 30? - sharewise
Thurston Springer Miller Herd & Titak Inc. Purchases 673 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending Stock - MSN
How Is The Market Feeling About Vertex Pharmaceuticals? - Benzinga
Burney Co. Has $15.21 Million Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Assenagon Asset Management S.A. Boosts Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today - Benzinga
Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials - Yahoo Finance
40 Under 40: Mnwabisi Mbangata, Vertex Pharmaceuticals - MM+M Online
Vertex Therapeutics: The Pain Comes With The Territory For Suzetrigine (VRTX) - Seeking Alpha
Vertex Pharmaceuticals' SWOT analysis: stock outlook balances innovation and valuation - Investing.com
Vertex Pharmaceuticals' (VRTX) "Outperform" Rating Reaffirmed at William Blair - MarketBeat
JPM25: Vertex CEO says pain is its next multi-billion franchise - FirstWord Pharma
Vertex Pharmaceuticals Incorporated : J.P. Morgan Healthcare Conference Presentation 2025 - Marketscreener.com
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Bought by Czech National Bank - MarketBeat
International Assets Investment Management LLC Sells 323,990 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings - Yahoo Finance
Zai Lab, Vertex Pharmaceuticals announce povetacicept license agreement - Yahoo Finance
US FDA approves Vertex Pharma's triple combo cystic fibrosis treatment - MSN
Vertex Pharmaceuticals (VRTX) Stock Moves -0.62%: What You Should Know - Yahoo Finance
Forecasting The Future: 23 Analyst Projections For Vertex Pharmaceuticals - Benzinga
CCM Investment Advisers LLC Sells 7,770 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) - MarketBeat
Vertex out-licenses povetacicept to Zai Lab - The Pharma Letter
Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore - BioSpace
Vertex Pharmaceuticals Incorporated (VRTX) Slid due to Setbacks In Clinical Trials - MSN
Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target Cut to $460.00 by Analysts at Wells Fargo & Company - MarketBeat
Vertex Pharmaceuticals Incorporated and Zai Lab Limited Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore - Marketscreener.com
Pfizer Is ‘Too Low To Sell, Let Dividend Do Its Job': Jim CramerNVIDIA (NASDAQ:NVDA), Pfizer (NYSE:PFE) - Benzinga
Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore - Business Wire
Vertex Pharmaceuticals Earnings Preview: What to Expect - Nasdaq
Vertex Pharmaceuticals Earnings Preview: What To Expect - Barchart
Finanzdaten der Vertex Pharmaceuticals Inc-Aktie (VRTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.68%
2.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):